Markets
ADC Therapeutics SA (ADCT)
ADCTNYSEBiotechnology: Pharmaceutical Preparations
$1.51
-0.1600 (-9.58%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.51 +0.33%
-9.58% 1D
- Market cap
- $192.14m
- P/E
- –
- EPS, last 4 quarters
- $-0.5200
- Dividend yield
- –
- Day range
- $1.47 to $1.73
- 52-week range
- $0.7796 to $4.98
- Average volume
- 192.0k
- Previous close
- $1.67
Analysts
2 coveringBuy1 buy, 1 hold, 0 sell
Targets a year out average $3.50, +131.8% from here
$2.00now $1.51$5.00
Earnings
next estimate $-0.2300Next report
Dec 2025
+87.5%
Mar 2026
-10.5%
Jun 2026
+42.1%
Sep 2026
+23.8%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $16.43m | $23.06m | $20.85m | $19.25m |
| Gross profit | $15.22m | $21.36m | $17.24m | $16.90m |
| Operating income | -$30.97m | -$17.92m | -$25.25m | -$25.41m |
| Net income | -$40.97m | -$6.41m | -$32.97m | -$16.57m |
Last four quarters: revenue $79.58m, margin -121.8%, free cash flow –
News
8 latest- ADC Therapeutics SA Reports Third Quarter 2026 Net Product Revenue of $21.0 million and Cash of $189.2 millionFintel · 1 day ago
- ADC Therapeutics Q3 Product Revenue Rises 33%; Cash Runway Extends Into 2029; Stock Down RTTNews · 1 day ago
- ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue EstimatesZacks · 1 day ago
- BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue EstimatesZacks · 5 days ago
- ADC Therapeutics SA Announces ZYNLONTA Clinical Trial Data and Financial RestructuringFintel · 6 days ago
- ADC Therapeutics Reports Strong Lymphoma Responses, Plans Phase III StudyMarketBeat · 6 days ago
- ADC Therapeutics Announces Japan Filing For ZYNLONTA In Relapsed Or Refractory Lymphoma RTTNews · Oct 29, 2026
- NeoGenomics (NEO) Q3 Earnings and Revenues Beat EstimatesZacks · Oct 28, 2026
The company
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- Region
- Europe
- Website
- adctherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.